Vitrolife (Swedish IVF equipment/consumables) dropped 18% to 52-week lows on Q4 earnings. The stock now trades down 28% on the year. The market puked on margin compression — EBITDA margin fell from 35.1% (Q4 2024) to 28.2% (Q4 2025). But the underlying business tells a different story.

What Actually Happened

Organic growth was 6% in Q4 and 4% for the full year (local currency, excluding discontinued products). The Americas business is surging: +9% growth overall, with the Technologies segment up 40%. Management confirmed they're cracking major clinic chains in North America — a strategic shift that's working.

The margin hit isn't operational decay. It's largely FX: the Swedish krona strengthened 17% against the dollar. For a Swedish exporter selling into dollar-denominated markets, that's a direct margin compressor. Management explicitly called out the comparison to Q4 2024, which was "exceptionally strong." They're guiding for margin recovery back to ≈59% in 2026.

They're also restructuring Genetic Services to exit lower-margin markets and tests — deliberately trading revenue for profitability focus.

Why This Matters

The market sold a headline (margin compression) without pricing the context (transitory FX, tough comp, strategic pruning). The Americas breakthrough is real — clinic chain penetration is hard to achieve in IVF equipment, and once you're in, switching costs are high.

You're buying a company growing 6% organically, cracking the North American clinic market, with management explicitly guiding margin recovery in 2026. The stock is at 52-week lows on what looks like FX noise.

The Risk

FX isn't entirely transitory if the SEK stays strong. Swedish exporter FX risk is real and hard to hedge. Margin compression could persist if currency trends hold. Market cap is $1.7B — outside the retail edge zone, so you're competing with institutions who have better FX modeling.

This could be a value trap, not a value opportunity. But at 52-week lows, with solid underlying growth and a credible margin recovery path, it's worth watching.